

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Sodium valproate

August 27, 2024

### **Therapeutic category**

Antiepileptics

Psychotropic agents

### **Non-proprietary name**

Sodium valproate

### **Safety measure**

PRECAUTIONS should be revised.

Revised language is underlined.

Current	Revision
15. OTHER PRECAUTIONS 15.1 Information Based on Clinical Uses (N/A)	15. OTHER PRECAUTIONS 15.1 Information Based on Clinical Uses <u>There has been an observational study performed in Scandinavian countries which suggests that infants/children with paternal exposure to sodium valproate within 3 months prior to conception had an increased risk of neurodevelopmental disorder compared with those with paternal exposure to lamotrigine or levetiracetam (adjusted hazard ratio 1.50 [95% confidence interval: 1.09–2.07]), although the causal relationship to sodium valproate is unclear. On the other hand, there has been an overseas observational study in fathers with epilepsy which showed that infants/children with paternal exposure to sodium valproate within 120 days prior to conception did not have a statistically significant increased risk of neurodevelopmental disorder compared with those with no paternal exposure to sodium valproate.</u>

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.

[References] PASS -Paternal exposure to valproate -Updated Abstract Following Reanalysis of Norway Data of Corrigendum to Final Study Report Version 1.1 and Addendum Version 2 Valproate EU consortium Stand Alone Abstract V2.0:  
[https://catalogues.ema.europa.eu/system/files/2024-02/Valproate\\_PASS\\_Abstract\\_V2.0\\_0.pdf](https://catalogues.ema.europa.eu/system/files/2024-02/Valproate_PASS_Abstract_V2.0_0.pdf)  
Christensen J, et al.: JAMA Netw Open. 2024; 7: e2414709